Melanocortin 1 receptor (MC1R) variants in high melanoma risk patients are associated with specific dermoscopic ABCD features

Acta Dermato-Venereologica

Volumn 92, Issue 6, 2012, Pages 587-592

  Quint, Koen D ^a   van der Rhee, Jasper I ^a   Gruis, Nelleke A ^a   ter Huurne, Jeanet A ^a   Wolterbeek, Ron ^a   van der Stoep, Nienke ^a   Bergman, Wilma ^a   Kukutsch, Nicole A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atypical naevi; CDKN2A; Dermoscopy; MC1R; Melanoma; Red hair; Total dermoscopy score

Indexed keywords

MELANOCORTIN 1 RECEPTOR;

ALLELE; ARTICLE; CANCER PATIENT; CDKN2A GENE; CLINICAL FEATURE; EPILUMINESCENCE MICROSCOPY; FOUNDER EFFECT; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAIR COLOR; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MC1R GENE; MELANOMA; NEVUS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR GENE; SCORING SYSTEM; SKIN COLOR; SKIN PIGMENTATION; TOTAL DERMOSCOPY SCORE;

CHI-SQUARE DISTRIBUTION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DERMOSCOPY; GENETIC PREDISPOSITION TO DISEASE; HAIR COLOR; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MELANOMA; MUTATION; NEVUS, PIGMENTED; PHENOTYPE; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RECEPTOR, MELANOCORTIN, TYPE 1; RISK FACTORS; SKIN; SKIN NEOPLASMS; SKIN PIGMENTATION;

EID: 84867791226     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1457     Document Type: Article

References (22)

1. Bosetti C, La Vecchia C, Naldi L, Lucchini F, Negri E, Levi F. Mortality from cutaneous malignant melanoma in Europe. Has the epidemic levelled off? Melanoma Res 2004; 14: 301-309.
2. de Vries E, Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004; 40: 2355-2366.
3. Busca R, Ballotti R. Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res 2000; 13: 60-69.
4. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, et al. Melanocortin 1 Receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair colour. J Invest Dermatol 2001; 117: 294-300.
5. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11: 328-330.
6. Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996; 5: 1663-1666.
7. Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000; 66: 176-186.
8. van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001; 69: 774-779.
9. Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, et al. MC1R variants, melanoma and red hair colour phenotype: a meta-analysis. Int J Cancer 2008; 122: 2753-2760.
10. Pastorino L, Cusano R, Bruno W, Lantieri F, Origone P, Barile M, et al. Novel MC1R variants in Ligurian melanoma patients and controls. Hum Mutat 2004; 24: 103.
11. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
12. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007; 44: 99-106.
13. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996; 12: 97-99.
14. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
15. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995; 10: 351-353.
16. Benelli C, Roscetti E, Pozzo VD, Gasparini G, Cavicchini S. The dermoscopic versus the clinical diagnosis of melanoma. Eur J Dermatol 1999; 9: 470-476.
17. Bafounta ML, Beauchet A, Aegerter P, Saiag P. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanomas? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol 2001; 137: 1343-1350.
18. Ascierto PA, Palmieri G, Celentano E, Parasole R, Caracò C, Daponte A, et al. Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. The Melanoma Cooperative Study. Br J Dermatol. 2000; 142: 893-898.
19. Cuéllar F, Puig S, Kolm I, Puig-Butille J, Zaballos P, Martí-Laborda R, et al. Dermoscopic features of melanomas associated with MC1R variants in Spanish CDKN2A mutation carriers. Br J Dermatol 2009; 160: 48-53.
20. de Snoo FA, Bergman W, Gruis NA. Familial melanoma: a complex disorder leading to controversy on DNA testing. Fam Cancer 2003; 2: 109-116.
21. Nachbar F, Stolz W, Merkle T Cognetta AB, Vogt T, Landthaler M, et al. The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions. Am Acad Dermatol 1994; 30: 551-559.
22. Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM. Increased melanocytic naevi and naevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree. J Invest Dermatol 2008; 128: 2122-2125.